Jounce Therapeutics, Inc.
Jounce Therapeutics, Inc. (JNCE) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · JNCE · as of Jun 30, 2023
Ownership Breakdown
1
Institutional Holders
▼ 84 vs Q1
$917,823
Total Inst. Value
▼ $63.14M vs Q1
52.64M
Shares Outstanding
freeFloat 56.63%
669,944
13F Shares Held
▼ 33.87M vs Q1
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
JNCE largest shareholders · institutional ownership
Q2 2023 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
OPALEYE MANAGEMENT INC. biological products, (no diagnostic substances) | 669.9K | 1.30% | 1.30% | $917.82M | Aug 14, 2023 | ▼ 2.21M |
FIDUCIARY TRUST CO biological products, (no diagnostic substances) | 0 | 0.00% | 0.00% | $0 | Aug 1, 2023 | EXIT |
PRICE T ROWE ASSOCIATES INC /MD/ biological products, (no diagnostic substances) | 0 | 0.00% | 0.00% | $0 | Aug 14, 2023 | EXIT |
BANK OF AMERICA CORP /DE/ biological products, (no diagnostic substances) | 0 | 0.00% | 0.00% | $0 | Aug 14, 2023 | EXIT |
WELLS FARGO & COMPANY/MN biological products, (no diagnostic substances) | 0 | 0.00% | 0.00% | $0 | Aug 15, 2023 | EXIT |
NORTHERN TRUST CORP biological products, (no diagnostic substances) | 0 | 0.00% | 0.00% | $0 | Aug 11, 2023 | EXIT |
FRANKLIN RESOURCES INC biological products, (no diagnostic substances) | 0 | 0.00% | 0.00% | $0 | Aug 11, 2023 | EXIT |
STATE STREET CORP biological products, (no diagnostic substances) | 0 | 0.00% | 0.00% | $0 | Aug 14, 2023 | EXIT |
VANGUARD GROUP INC biological products, (no diagnostic substances) | 0 | 0.00% | 0.00% | $0 | Aug 14, 2023 | EXIT |
JPMORGAN CHASE & CO biological products, (no diagnostic substances) | 0 | 0.00% | 0.00% | $0 | Aug 11, 2023 | EXIT |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q2 2023 vs prior quarter
Q2 2023
0
Increased
+0 shares0
New Positions
first time holders1
Decreased
−2.21M shares49
Sold Out
fully exitedNet shares change (top 50)
2.21M
+0 / −2.21M
Net new holders
-50
0 new / 49 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
JNCE insider trading · insider activity
Source: SEC Form 4
2
Buy transactions
60
Sell transactions
0.03
Buy/Sell ratio
$9M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Concentra Biosciences, LLC 10 percent owner | May 3, 2023 | J-Other | 10,000 | $9737.70 | $97.38M | 10.0K | Form 4 ↗ |
TANG KEVIN C
| May 3, 2023 | J-Other | 10,000 | $9737.70 | $97.38M | 10.0K | Form 4 ↗ |
TANG KEVIN C
| May 3, 2023 | U-Tender | 5,300,087 | $1.85 | $9.81M | 0 | Form 4 ↗ |
Salter-Cid Luisa director | May 3, 2023 | D-Return | 7,850 | $7.27 | $57.1K | 0 | Form 4 ↗ |
Salter-Cid Luisa director | May 3, 2023 | D-Return | 31,400 | $12.36 | $388.1K | 0 | Form 4 ↗ |
Salter-Cid Luisa director | May 3, 2023 | D-Return | 20,000 | $2.80 | $56.0K | 0 | Form 4 ↗ |
Raythatha Jigar director | May 3, 2023 | D-Return | 31,400 | $6.47 | $203.2K | 0 | Form 4 ↗ |
Raythatha Jigar director | May 3, 2023 | D-Return | 20,000 | $2.80 | $56.0K | 0 | Form 4 ↗ |
MURRAY RICHARD /CA/ director | May 3, 2023 | U-Tender | 188,778 | $1.85 | $349.2K | 1 | Form 4 ↗ |
MURRAY RICHARD /CA/ director | May 3, 2023 | D-Return | 125,010 | $4.40 | $550.0K | 0 | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Jounce Therapeutics, Inc. (JNCE) is primarily owned by institutional investors, who hold approximately 1.3% of total shares outstanding. Company insiders own approximately 43.37%, while retail and public investors account for the remaining 55.35%.
The largest institutional shareholder of Jounce Therapeutics, Inc. is OPALEYE MANAGEMENT INC., holding approximately 669,944 shares — equal to 1.30% of outstanding shares — as of June 30, 2023.
A total of 1 institutional investors currently hold JNCE stock, with a combined institutional value of approximately $917,823 as of the most recent 13F filing period.
Frequently asked questions
JNCE ownershipJounce Therapeutics, Inc. (JNCE) is primarily owned by institutional investors, who hold approximately 1.3% of shares. The largest shareholder is OPALEYE MANAGEMENT INC. with a 1.30% stake. Company insiders hold 43.37%. Data sourced from SEC Form 13F as of June 30, 2023.